Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Herpes Simplex Virus Encephalitis in Patients with Autoimmune Conditions or Exposure to Immunomodulatory Medications
Neurol 102:e209297, Tang,A.,et al, 2024
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised
Neurol 79:2125-2132, Tan, L.,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Analysis of Relapses in Anti-NMDAR Encephalitis
Neurol 77:996-999, Gabilondo, I.,et al, 2011
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
JAMA 296:2832-2838, Munger,K.L.,et al, 2006